
This episode discusses the transformative kidney medications SGLT2 inhibitors, GLP-1s, and finerenone, and their impact on kidney care for those living with chronic kidney disease.
Have you heard of Farxiga (dapagliflozin), Jardiance (empagliflozin), Ozempic, Wegovy, Mounjaro, or finerenone, but aren’t quite sure what they do or whether they’re right for people living with kidney disease? In this episode of Diary of a Kidney Warrior Podcast, host Dee Moore is joined by Professor Alex, Consultant Nephrologist and researcher, for an essential conversation about some of the biggest breakthroughs in kidney medicine in recent years. Originally developed for diabetes, SGLT2 inhibitors have transformed kidney care and are now helping to protect kidney function, reduce protein in the urine and improve outcomes for many people living with chronic kidney disease (CKD). We also explore the growing role of GLP-1 receptor agonists and finerenone, and explain what patients need to know about these treatments. Whether you’re living with chronic kidney disease, caring for someone who is, or you’re a healthcare professional wanting a patient-friendly explanation, this episode is packed with practical, evidence-based information. In this episode, you’ll learn: ✅ What SGLT2 inhibitors are and how they protect the kidneys ✅ Why medications developed for diabetes are now…
Host: Dee Moore
Guest: Professor Alex
Products: Farxiga, dapagliflozin, Jardiance, empagliflozin, Ozempic, Wegovy, Mounjaro, finerenone
Explore listener stats, chart rankings, contacts and more on the Diary of a Kidney Warrior Podcast | Living with Kidney Disease podcast page.